First Trust Exchange-Traded Fund VI First Trust New Constructs Core Earnings Leaders ETF (ARCA: FTCE)

最新ニュース First Trust Exchange-Traded Fund VI First Trust New Constructs Core Earnings Leaders ETF (ARCA:FTCE)

First Trust New Constructs Core Earnings Leaders ETF

First Trust Exchange-Traded Fund VI First Trust New Constructs Core Earnings Leaders ETF

PG&amp;E Corporation is reaffirming 2025 GAAP earnings guidance in the range of $1.30 to $1.36 per share. Factors driving GAAP earnings include costs related to unrecoverable interest expense of $350 million to $400 million after tax and other earnings factors, including allowance for funds used during construction, incentive revenues, tax benefits, and cost savings, net of below-the-line costs. Additional factors include the amortization of the Wildfire Fund asset and accretion of the related Wildfire Fund liability, costs related to PG&amp;E Corporation's and the Utility's reorganization cases under Chapter 11, wildfire-related costs, and investigation remedies, partially offset by prior period net regulatory impact.
The guidance range for projected 2025 non-GAAP core earnings increased from $1.47 to $1.51 per share to $1.48 to $1.52 per share. The guidance range for non-core items, which management does not consider representative of ongoing earnings, is $360 million to $400 million after tax.
Guidance is based on various assumptions and forecasts, including those relating to authorized revenues, future expenses, capital expenditures, rate base, equity issuances, and certain other factors.

News

Guidance

PG&E Raised 2025 Adj EPS To $1.48-$1.52 (From $1.47 - $1.51 Earlier) Vs. Est $1.49

Avient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVNT#NYSE">AVNT</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.48 by 2.08 percent. This is a 5.77 percent decrease over earnings of $0.52 per share from the same period last year. The company reported quarterly sales of $746.500 million which missed the analyst consensus estimate of $749.020 million by 0.34 percent. This is a 3.82 percent increase over sales of $719.000 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

AVNT

Avient Q4 2024 Adj. EPS $0.49 Beats $0.48 Estimate, Sales $746.500M Miss $749.020M Estimate

OCFT

OneConnect Launches Its Proprietary AI Agent Platform, Integrating Open-source Large Language Models Including DeepSeek And Qwen

The project reached a final investment decision ("FID") in mid-December 2024. When the project is fully operational, which is expected in the first quarter of 2026 (subject to receipt of all required permits), the facility is forecasted to achieve an average sequestration rate of approximately 90,000 metric tons per year of CO2 equivalent.
The new CCS facility adds to BKV's carbon capture, utilization and sequestration ("CCUS") portfolio, which includes the operational CCS facility at the Company's Barnett Zero site in north Texas and the Cotton Cove CCS project, which has reached FID and is expected to begin initial sequestration operations in the first half of 2026.

General

BKV Announced A Strategic Partnership With A Midstream Energy Company To Develop A New Carbon Capture And Sequestration Facility At A Currently Operating Natural Gas Plant In South Texas

Deere Sees FY Net Income Of $5.0B-$5.5B. Outlook Does Not Reflect The Impacts Of Potential Import Tariffs By U.S.

PG&amp;E (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>) reported quarterly earnings of $0.31 per share which met the analyst consensus estimate. This is a 34.04 percent decrease over earnings of $0.47 per share from the same period last year.

PG&E Q4 2024 Adj. EPS $0.31, Inline

IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) reported quarterly losses of $(1.49) per share which missed the analyst consensus estimate of $(0.64) by 132.81 percent. This is a 186.54 percent decrease over losses of $(0.52) per share from the same period last year. The company reported quarterly sales of $7.00 million which beat the analyst consensus estimate of $4.67 million by 50.00 percent. This is a 78.43 percent increase over sales of $3.92 million the same period last year.

IDYA

IDEAYA Biosciences Q4 2024 GAAP EPS $(1.49) Misses $(0.64) Estimate, Sales $7.00M Beat $4.67M Estimate

IFRS gross margin will be continuously negatively impacted in the short-term because of our ongoing and accelerated battery upgrade initiatives which is expected to be completed by the end of 2025.

Gogoro Sees FY25 Between $295M-$315M On A Constant Currency Basis Which Would Reflect 2025 Taiwan Market Condition And Conversion Rate

Scotiabank analyst George Farmer initiates coverage on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Sector Outperform rating and announces Price Target of $102.

Price Target

Initiation

Analyst Ratings

VKTX

Scotiabank Initiates Coverage On Viking Therapeutics with Sector Outperform Rating, Announces Price Target of $102

Education

Contracts

NAMI

Jinxin Technology Announced An In-depth Strategic Partnership With Tencent Cloud And Sichuan Education Press To Co-develop Large-scale And Commercial Ai Learning Solutions For K-12 Students

The facilities under the tolling agreements are expected to have a combined capacity of approximately 300MW/1200MWh.

Ormat Technologies Has Won A Tender Issued By The Israeli Electricity Authority And Has Been Awarded Two Separate 15-Year Tolling Agreements For Two Energy Storage Facilities

Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) reported quarterly earnings of $3.19 per share which beat the analyst consensus estimate of $3.14 by 1.59 percent. This is a 48.8 percent decrease over earnings of $6.23 per share from the same period last year. The company reported quarterly sales of $8.51 billion which beat the analyst consensus estimate of $7.70 billion by 10.52 percent. This is a 30.18 percent decrease over sales of $12.19 billion the same period last year.

Deere Q1 2025 GAAP EPS $3.19 Beats $3.14 Estimate, Sales $8.51B Beat $7.70B Estimate

Citigroup analyst Andres Cardona upgrades Vista Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIST#NYSE">VIST</a>) from Neutral to Buy and announces $66 price target.

Upgrades

VIST

Citigroup Upgrades Vista Energy to Buy, Announces $66 Price Target

LXP Industrial Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LXP#NYSE">LXP</a>) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.15 by 6.67 percent. This is a 5.88 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $100.851 million which beat the analyst consensus estimate of $83.837 million by 20.29 percent. This is a 21.57 percent increase over sales of $82.956 million the same period last year.

LXP Industrial Trust Q4 2024 FFO $0.16 Beats $0.15 Estimate, Sales $100.851M Beat $83.837M Estimate

<ul>
<li>Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in MTAP-deletion NSCLC</li>
<li>The potential first-in-class clinical combination of IDE397 and Trodelvy targets two mechanistically distinct and complementary nodes of MTAP-deletion in solid tumors</li>
<li>MTAP-deletion prevalence in NSCLC is estimated to be approximately 15%</li>
</ul>

Biotech

Health Care

GILD

IDEAYA Biosciences Announced An Additional Clinical Study Collaboration And Supply Agreement With Gilead Sciences To Evaluate IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan) For Methylthioadenosine Phosphorylase-Deletion Non-Small Cell Lung Cancer

Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) reported quarterly losses of $(0.25) per share. This is a 108.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $73.007 million in sales this quarter. This is a 20.24 percent decrease over sales of $91.530 million the same period last year.

Gogoro Q4 2024 GAAP EPS $(0.25) Down From $(0.12) YoY, Sales $73.007M Down From $91.530M YoY

West Pharmaceutical Services Sees FY25 Adj. EPS $6.00-$6.20 vs. $7.44 Est., Revenue $2.875B-$2.905B vs. $3.042B Est.

YETI Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YETI#NYSE">YETI</a>) reported quarterly earnings of $1.00 per share which beat the analyst consensus estimate of $0.93 by 7.53 percent. This is a 11.11 percent increase over earnings of $0.90 per share from the same period last year. The company reported quarterly sales of $546.54 million which missed the analyst consensus estimate of $551.97 million by 0.98 percent. This is a 5.15 percent increase over sales of $519.79 million the same period last year.

YETI

YETI Holdings Q4 2024 Adj EPS $1.00 Beats $0.93 Estimate, Sales $546.54M Miss $551.97M Estimate

Genesis Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEL#NYSE">GEL</a>) reported quarterly losses of $(0.58) per share. This is a 625 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $725.553 million in sales this quarter. This is a 6.27 percent decrease over sales of $774.104 million the same period last year.

Genesis Energy Q4 2024 GAAP EPS $(0.58) Down From $(0.08) YoY, Sales $725.553M Down From $774.104M YoY

Walker &amp; Dunlop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WD#NYSE">WD</a>) reported quarterly earnings of $1.34 per share which beat the analyst consensus estimate of $1.22 by 9.84 percent. This is a 5.63 percent decrease over earnings of $1.42 per share from the same period last year. The company reported quarterly sales of $341.45 million which beat the analyst consensus estimate of $311.66 million by 9.56 percent. This is a 24.46 percent increase over sales of $274.34 million the same period last year.

Comments

First Trust Exchange-Traded Fund VI First Trust New Constructs Core Earnings Leaders ETF

ニュース

最新ニュース First Trust Exchange-Traded Fund VI First Trust New Constructs Core Earnings Leaders ETF (ARCA:FTCE)

ニュース

パートナーシップ

ベンジンガ・グローバル